Adding durvalumab to neoadjuvant chemotherapy maintains quality of life in resectable NSCLC
Adding durvalumab to neoadjuvant chemotherapy maintains quality of life in resectable NSCLC
Digital pathology superior to manual SP263 PD-L1 TC scoring for stage II-IIIA high PD-L1 expression NSCLC
Taletrectinib superior to crizotinib in ROS1-positive non-small cell lung cancer
Perioperative durvalumab in addition to neoadjuvant chemotherapy shows positive results in patients with stage IIIa(N2) NSCLC
Pembrolizumab plus cCRT continue to demonstrate antitumour activity in advanced NSCLC
Dermatologic adverse events in the treatment of NSCLC with amivantamab plus lazertinib significantly reduced
Addition of radical prostatectomy to systemic treatment improves survival in oligometastatic prostate cancer
NeuroSAFE-guided RARP improves surgical precision for patients with localised prostate cancer
The added value of integrative medicine
Urine test could reduce post-op scans for kidney cancer by half
Micro-ultrasound is as effective as MRI in detecting prostate cancer
Bone-protective agents given with enzalutamide with or without radium-223 show greater survival benefits in mCRPC